Continuous intravenous heparin administration in humans causes a decrease in serum lipolytic activity and accumulation of chylomicrons in circulation.

Heparin is a well-known, widely used anticoagulant drug. In addition to its anticoagulant properties, however, it also has a marked influence on fat metabolism. Postprandial lipoproteins may contribute significantly to the development of coronary heart disease. Therefore, it is important to evaluate...

Full description

Bibliographic Details
Main Authors: M Weintraub, T Rassin, S Eisenberg, Y Ringel, I Grosskopf, A Iaina, G Charach, M Liron, A Rubinstein
Format: Article
Language:English
Published: Elsevier 1994-02-01
Series:Journal of Lipid Research
Online Access:http://www.sciencedirect.com/science/article/pii/S0022227520412118
id doaj-9858faa2c521425bb8b56eb01ef35697
record_format Article
spelling doaj-9858faa2c521425bb8b56eb01ef356972021-04-26T05:52:09ZengElsevierJournal of Lipid Research0022-22751994-02-01352229238Continuous intravenous heparin administration in humans causes a decrease in serum lipolytic activity and accumulation of chylomicrons in circulation.M Weintraub0T Rassin1S Eisenberg2Y Ringel3I Grosskopf4A Iaina5G Charach6M Liron7A Rubinstein8Department of Internal Medicine C, Tel Aviv Medical Center, Israel.Department of Internal Medicine C, Tel Aviv Medical Center, Israel.Department of Internal Medicine C, Tel Aviv Medical Center, Israel.Department of Internal Medicine C, Tel Aviv Medical Center, Israel.Department of Internal Medicine C, Tel Aviv Medical Center, Israel.Department of Internal Medicine C, Tel Aviv Medical Center, Israel.Department of Internal Medicine C, Tel Aviv Medical Center, Israel.Department of Internal Medicine C, Tel Aviv Medical Center, Israel.Department of Internal Medicine C, Tel Aviv Medical Center, Israel.Heparin is a well-known, widely used anticoagulant drug. In addition to its anticoagulant properties, however, it also has a marked influence on fat metabolism. Postprandial lipoproteins may contribute significantly to the development of coronary heart disease. Therefore, it is important to evaluate the effects of heparin on these lipoproteins. The effect of continuous heparin administration on postprandial lipoprotein metabolism was studied in 11 patients with thromboembolic disease. Results were compared with those in a group of six patients given no heparin. Two vitamin A-fat loading tests were done: the first, 5 days before heparin was started and the second, on the fourth day of continuous heparin drip of 1000 U/h, maintaining PTT levels at twice the baseline. To study the effect of acute heparin, an additional fat loading test was done in five patients on the first day of heparin treatment. Vitamin A, specifically labels intestinally derived lipoproteins with retinyl palmitate (RP). The concentrations of chylomicron (Sf > 1000)- and nonchylomicron (Sf < 100)-retinyl palmitate were measured for 10 h postprandially. Four days of continuous intravenous heparin administration increased the area below the chylomicron RP curve from 11091 +/- 4393 to 17684 +/- 5949 micrograms/l.h (P < 0.003). When measured on the first day of heparin treatment in five patients, the area of the chylomicron fraction was reduced from 16678 +/- 6895 to 10474 +/- 3893 micrograms/l.h (P < 0.05). Postheparin lipoprotein lipase activity was significantly lower on the fourth day of heparin, administration than before treatment: 1.8 +/- 1.1 vs. 4.1 +/- 1.3 mumol/FFA per ml per h, respectively (P < 0.0005). In the six control patients with thromboembolic disease in whom heparin therapy was not indicated, no changes in postprandial lipoprotein levels or in lipolytic activity during hospitalization were found. The study demonstrates that 4 days of heparin administration causes an accumulation of chylomicrons in the circulation, most probably as a result of a marked decrease in serum lipolytic activity.http://www.sciencedirect.com/science/article/pii/S0022227520412118
collection DOAJ
language English
format Article
sources DOAJ
author M Weintraub
T Rassin
S Eisenberg
Y Ringel
I Grosskopf
A Iaina
G Charach
M Liron
A Rubinstein
spellingShingle M Weintraub
T Rassin
S Eisenberg
Y Ringel
I Grosskopf
A Iaina
G Charach
M Liron
A Rubinstein
Continuous intravenous heparin administration in humans causes a decrease in serum lipolytic activity and accumulation of chylomicrons in circulation.
Journal of Lipid Research
author_facet M Weintraub
T Rassin
S Eisenberg
Y Ringel
I Grosskopf
A Iaina
G Charach
M Liron
A Rubinstein
author_sort M Weintraub
title Continuous intravenous heparin administration in humans causes a decrease in serum lipolytic activity and accumulation of chylomicrons in circulation.
title_short Continuous intravenous heparin administration in humans causes a decrease in serum lipolytic activity and accumulation of chylomicrons in circulation.
title_full Continuous intravenous heparin administration in humans causes a decrease in serum lipolytic activity and accumulation of chylomicrons in circulation.
title_fullStr Continuous intravenous heparin administration in humans causes a decrease in serum lipolytic activity and accumulation of chylomicrons in circulation.
title_full_unstemmed Continuous intravenous heparin administration in humans causes a decrease in serum lipolytic activity and accumulation of chylomicrons in circulation.
title_sort continuous intravenous heparin administration in humans causes a decrease in serum lipolytic activity and accumulation of chylomicrons in circulation.
publisher Elsevier
series Journal of Lipid Research
issn 0022-2275
publishDate 1994-02-01
description Heparin is a well-known, widely used anticoagulant drug. In addition to its anticoagulant properties, however, it also has a marked influence on fat metabolism. Postprandial lipoproteins may contribute significantly to the development of coronary heart disease. Therefore, it is important to evaluate the effects of heparin on these lipoproteins. The effect of continuous heparin administration on postprandial lipoprotein metabolism was studied in 11 patients with thromboembolic disease. Results were compared with those in a group of six patients given no heparin. Two vitamin A-fat loading tests were done: the first, 5 days before heparin was started and the second, on the fourth day of continuous heparin drip of 1000 U/h, maintaining PTT levels at twice the baseline. To study the effect of acute heparin, an additional fat loading test was done in five patients on the first day of heparin treatment. Vitamin A, specifically labels intestinally derived lipoproteins with retinyl palmitate (RP). The concentrations of chylomicron (Sf > 1000)- and nonchylomicron (Sf < 100)-retinyl palmitate were measured for 10 h postprandially. Four days of continuous intravenous heparin administration increased the area below the chylomicron RP curve from 11091 +/- 4393 to 17684 +/- 5949 micrograms/l.h (P < 0.003). When measured on the first day of heparin treatment in five patients, the area of the chylomicron fraction was reduced from 16678 +/- 6895 to 10474 +/- 3893 micrograms/l.h (P < 0.05). Postheparin lipoprotein lipase activity was significantly lower on the fourth day of heparin, administration than before treatment: 1.8 +/- 1.1 vs. 4.1 +/- 1.3 mumol/FFA per ml per h, respectively (P < 0.0005). In the six control patients with thromboembolic disease in whom heparin therapy was not indicated, no changes in postprandial lipoprotein levels or in lipolytic activity during hospitalization were found. The study demonstrates that 4 days of heparin administration causes an accumulation of chylomicrons in the circulation, most probably as a result of a marked decrease in serum lipolytic activity.
url http://www.sciencedirect.com/science/article/pii/S0022227520412118
work_keys_str_mv AT mweintraub continuousintravenousheparinadministrationinhumanscausesadecreaseinserumlipolyticactivityandaccumulationofchylomicronsincirculation
AT trassin continuousintravenousheparinadministrationinhumanscausesadecreaseinserumlipolyticactivityandaccumulationofchylomicronsincirculation
AT seisenberg continuousintravenousheparinadministrationinhumanscausesadecreaseinserumlipolyticactivityandaccumulationofchylomicronsincirculation
AT yringel continuousintravenousheparinadministrationinhumanscausesadecreaseinserumlipolyticactivityandaccumulationofchylomicronsincirculation
AT igrosskopf continuousintravenousheparinadministrationinhumanscausesadecreaseinserumlipolyticactivityandaccumulationofchylomicronsincirculation
AT aiaina continuousintravenousheparinadministrationinhumanscausesadecreaseinserumlipolyticactivityandaccumulationofchylomicronsincirculation
AT gcharach continuousintravenousheparinadministrationinhumanscausesadecreaseinserumlipolyticactivityandaccumulationofchylomicronsincirculation
AT mliron continuousintravenousheparinadministrationinhumanscausesadecreaseinserumlipolyticactivityandaccumulationofchylomicronsincirculation
AT arubinstein continuousintravenousheparinadministrationinhumanscausesadecreaseinserumlipolyticactivityandaccumulationofchylomicronsincirculation
_version_ 1721508288932085760